Eli Lilly

Eli Lilly is a pharmaceutical company that develops and markets drugs, including treatments for diabetes, cancer, and obesity. It is currently focused on protecting its obesity drug retatrutide from the black market and expanding patient access to it.

Why it’s in the news: It is in the news due to legal action against pharmacies over its new weight-loss drug and new data on its potential heart benefits.

Latest on Eli Lilly

• STAT+: Eli Lilly targets booming black market for retatrutide
• Eli Lilly is suing pharmacies and peptide vendors over sale of its next big weight-loss drug: retatrutide
• STAT+: Eli Lilly to allow more patients to apply for special access to unapproved obesity drug
• STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefit
• Pharma heavyweights Novo Nordisk and Eli Lilly clash over anti-obesity drug ads
• STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’
• 13F: S&A Financial Services holds Eli Lilly ($390,593)
• 13F: First National Bank Of Mount Dora Trust Investment Services holds Eli Lilly ($12M)
• 13F: Goodwin Investment Advisory holds Eli Lilly ($298,658)
• 13F: Prosperitas Financial Llc holds Eli Lilly ($6M)
• 13F: Sustainable Insight Capital Management Llc holds Eli Lilly ($12M)
• 13F: Concorde Asset Management Llc holds Eli Lilly ($782,576)

Connections

77 entities linked to Eli Lilly across the news graph.